Tags

Type your tag names separated by a space and hit enter

Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease.
Pharmacol Ther 2014; 141(3):272-82P&T

Abstract

Omega-3 (n-3) polyunsaturated fatty acids (n-3 PUFAs) have well documented anti-inflammatory properties, and consequently therapeutic potential in chronic inflammatory diseases. Here we discuss the effects of n-3 PUFAs on various inflammatory pathways and how this leads to alterations in the function of inflammatory cells, most importantly endothelial cells and leukocytes. Strong evidence indicates n-3 PUFAs are beneficial as a dietary supplement in certain diseases such as rheumatoid arthritis; however for other conditions such as asthma, the data are less robust. A clearer understanding of the pharmacology of n-3 PUFAs will help to establish targets to modulate chronic inflammatory diseases.

Authors+Show Affiliations

Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, The University of Birmingham, B15 2TT, UK.Human Development & Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, The University of Birmingham, B15 2TT, UK. Electronic address: g.e.rainger@bham.ac.uk.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24201219

Citation

Yates, Clara M., et al. "Pharmacology and Therapeutics of Omega-3 Polyunsaturated Fatty Acids in Chronic Inflammatory Disease." Pharmacology & Therapeutics, vol. 141, no. 3, 2014, pp. 272-82.
Yates CM, Calder PC, Ed Rainger G. Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther. 2014;141(3):272-82.
Yates, C. M., Calder, P. C., & Ed Rainger, G. (2014). Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacology & Therapeutics, 141(3), pp. 272-82. doi:10.1016/j.pharmthera.2013.10.010.
Yates CM, Calder PC, Ed Rainger G. Pharmacology and Therapeutics of Omega-3 Polyunsaturated Fatty Acids in Chronic Inflammatory Disease. Pharmacol Ther. 2014;141(3):272-82. PubMed PMID: 24201219.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. AU - Yates,Clara M, AU - Calder,Philip C, AU - Ed Rainger,G, Y1 - 2013/11/04/ PY - 2013/10/11/received PY - 2013/10/12/accepted PY - 2013/11/9/entrez PY - 2013/11/10/pubmed PY - 2014/9/16/medline KW - AA KW - ALA KW - Arachidonic acid KW - CD KW - COX KW - CVD KW - Crohn's disease KW - DHA KW - Docosahexaenoic acid KW - EC KW - EPA KW - Eicosanoid KW - Eicosapentaenoic acid KW - FFA KW - IBD KW - ICAM-1 KW - IL KW - Inflammation KW - LA KW - LOX KW - LT KW - LX KW - NPD KW - Omega-3 polyunsaturated fatty acid KW - PBMC KW - PD KW - PG KW - PI KW - RA KW - RCT KW - Resolvin KW - Rv KW - SPM KW - TNF KW - UC KW - VCAM-1 KW - alpha-linolenic acid KW - cardiovascular disease KW - cyclooxygensae KW - docosahexaenoic acid KW - eicosapentaenoic acid KW - endothelial cells KW - free fatty acids KW - inflammatory bowel diseases KW - intercellular adhesion molecule-1 KW - interleukin KW - leukotrienes KW - linoleic acid KW - lipoxin KW - lipoxygenase KW - neuroprotectin KW - n−3 PUFAs KW - omega-3 polyunsaturated fatty acids KW - peripheral blood mononuclear cell KW - phosphatidylinositol KW - prostaglandin KW - protectin KW - randomised controlled trial KW - resolvin KW - rheumatoid arthritis KW - specialised pro-resolving mediators KW - tumour necrosis factor KW - ulcerative colitis KW - vascular cell adhesion molecule-1 SP - 272 EP - 82 JF - Pharmacology & therapeutics JO - Pharmacol. Ther. VL - 141 IS - 3 N2 - Omega-3 (n-3) polyunsaturated fatty acids (n-3 PUFAs) have well documented anti-inflammatory properties, and consequently therapeutic potential in chronic inflammatory diseases. Here we discuss the effects of n-3 PUFAs on various inflammatory pathways and how this leads to alterations in the function of inflammatory cells, most importantly endothelial cells and leukocytes. Strong evidence indicates n-3 PUFAs are beneficial as a dietary supplement in certain diseases such as rheumatoid arthritis; however for other conditions such as asthma, the data are less robust. A clearer understanding of the pharmacology of n-3 PUFAs will help to establish targets to modulate chronic inflammatory diseases. SN - 1879-016X UR - https://www.unboundmedicine.com/medline/citation/24201219/Pharmacology_and_therapeutics_of_omega_3_polyunsaturated_fatty_acids_in_chronic_inflammatory_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(13)00215-5 DB - PRIME DP - Unbound Medicine ER -